 | • レポートコード：MRC2-11QY04127 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は卵巣がん治療薬のグローバル市場について調査・分析したレポートです。種類別（PARP、PD-L1、血管新生阻害剤）市場規模、用途別（病院、研究）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別卵巣がん治療薬の競争状況、市場シェア ・世界の卵巣がん治療薬市場：種類別市場規模 2015年-2020年（PARP、PD-L1、血管新生阻害剤） ・世界の卵巣がん治療薬市場：種類別市場規模予測 2021年-2026年（PARP、PD-L1、血管新生阻害剤） ・世界の卵巣がん治療薬市場：用途別市場規模 2015年-2020年（病院、研究） ・世界の卵巣がん治療薬市場：用途別市場規模予測 2021年-2026年（病院、研究） ・北米の卵巣がん治療薬市場分析：米国、カナダ ・ヨーロッパの卵巣がん治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの卵巣がん治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の卵巣がん治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの卵巣がん治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bristol Myers Squibb Company、Eli Lilly and Company、GlaxoSmithKline Plc、Janssen Pharmaceuticals、Genentech Inc.、Astra Zeneca、Boehringer Ingelheim GmbH、Hoffmann La Roche Ltd. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Ovarian cancer, and its rising incidence rate, is a growing concern worldwide. Market players that are currently engaged in the development of drugs and therapies for ovarian cancer stand to benefit by observing the latest trends and pipeline competitor products.
Market Analysis and Insights: Global Ovarian Cancer Therapeutics Market
The global Ovarian Cancer Therapeutics market size is projected to reach US$ 1867 million by 2026, from US$ 1764.3 million in 2020, at a CAGR of 5.4%% during 2021-2026.
Global Ovarian Cancer Therapeutics Scope and Market Size
Ovarian Cancer Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Ovarian Cancer Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Bristol Myers Squibb Company
Eli Lilly and Company
GlaxoSmithKline Plc
Janssen Pharmaceuticals
Genentech Inc.
Astra Zeneca
Boehringer Ingelheim GmbH
Hoffmann La Roche Ltd.
Market segment by Type, the product can be split into
PARP
PD-L1
Angiogenesis Inhibitors
Market segment by Application, split into
Hosptial
Research
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Ovarian Cancer Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Ovarian Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 PARP
1.4.3 PD-L1
1.4.4 Angiogenesis Inhibitors
1.5 Market by Application
1.5.1 Global Ovarian Cancer Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hosptial
1.5.3 Research
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Ovarian Cancer Therapeutics Market Perspective (2015-2026)
2.2 Global Ovarian Cancer Therapeutics Growth Trends by Regions
2.2.1 Ovarian Cancer Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Ovarian Cancer Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Ovarian Cancer Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Ovarian Cancer Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Ovarian Cancer Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Ovarian Cancer Therapeutics Players by Market Size
3.1.1 Global Top Ovarian Cancer Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Ovarian Cancer Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Ovarian Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Ovarian Cancer Therapeutics Market Concentration Ratio
3.2.1 Global Ovarian Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Ovarian Cancer Therapeutics Revenue in 2019
3.3 Ovarian Cancer Therapeutics Key Players Head office and Area Served
3.4 Key Players Ovarian Cancer Therapeutics Product Solution and Service
3.5 Date of Enter into Ovarian Cancer Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Ovarian Cancer Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Ovarian Cancer Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Ovarian Cancer Therapeutics Market Size by Application (2015-2020)
5.2 Global Ovarian Cancer Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Ovarian Cancer Therapeutics Market Size (2015-2020)
6.2 Ovarian Cancer Therapeutics Key Players in North America (2019-2020)
6.3 North America Ovarian Cancer Therapeutics Market Size by Type (2015-2020)
6.4 North America Ovarian Cancer Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Ovarian Cancer Therapeutics Market Size (2015-2020)
7.2 Ovarian Cancer Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Ovarian Cancer Therapeutics Market Size by Type (2015-2020)
7.4 Europe Ovarian Cancer Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Ovarian Cancer Therapeutics Market Size (2015-2020)
8.2 Ovarian Cancer Therapeutics Key Players in China (2019-2020)
8.3 China Ovarian Cancer Therapeutics Market Size by Type (2015-2020)
8.4 China Ovarian Cancer Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Ovarian Cancer Therapeutics Market Size (2015-2020)
9.2 Ovarian Cancer Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Ovarian Cancer Therapeutics Market Size by Type (2015-2020)
9.4 Japan Ovarian Cancer Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Ovarian Cancer Therapeutics Market Size (2015-2020)
10.2 Ovarian Cancer Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Ovarian Cancer Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Ovarian Cancer Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Ovarian Cancer Therapeutics Market Size (2015-2020)
11.2 Ovarian Cancer Therapeutics Key Players in India (2019-2020)
11.3 India Ovarian Cancer Therapeutics Market Size by Type (2015-2020)
11.4 India Ovarian Cancer Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Ovarian Cancer Therapeutics Market Size (2015-2020)
12.2 Ovarian Cancer Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Ovarian Cancer Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Ovarian Cancer Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Bristol Myers Squibb Company
13.1.1 Bristol Myers Squibb Company Company Details
13.1.2 Bristol Myers Squibb Company Business Overview
13.1.3 Bristol Myers Squibb Company Ovarian Cancer Therapeutics Introduction
13.1.4 Bristol Myers Squibb Company Revenue in Ovarian Cancer Therapeutics Business (2015-2020))
13.1.5 Bristol Myers Squibb Company Recent Development
13.2 Eli Lilly and Company
13.2.1 Eli Lilly and Company Company Details
13.2.2 Eli Lilly and Company Business Overview
13.2.3 Eli Lilly and Company Ovarian Cancer Therapeutics Introduction
13.2.4 Eli Lilly and Company Revenue in Ovarian Cancer Therapeutics Business (2015-2020)
13.2.5 Eli Lilly and Company Recent Development
13.3 GlaxoSmithKline Plc
13.3.1 GlaxoSmithKline Plc Company Details
13.3.2 GlaxoSmithKline Plc Business Overview
13.3.3 GlaxoSmithKline Plc Ovarian Cancer Therapeutics Introduction
13.3.4 GlaxoSmithKline Plc Revenue in Ovarian Cancer Therapeutics Business (2015-2020)
13.3.5 GlaxoSmithKline Plc Recent Development
13.4 Janssen Pharmaceuticals
13.4.1 Janssen Pharmaceuticals Company Details
13.4.2 Janssen Pharmaceuticals Business Overview
13.4.3 Janssen Pharmaceuticals Ovarian Cancer Therapeutics Introduction
13.4.4 Janssen Pharmaceuticals Revenue in Ovarian Cancer Therapeutics Business (2015-2020)
13.4.5 Janssen Pharmaceuticals Recent Development
13.5 Genentech Inc.
13.5.1 Genentech Inc. Company Details
13.5.2 Genentech Inc. Business Overview
13.5.3 Genentech Inc. Ovarian Cancer Therapeutics Introduction
13.5.4 Genentech Inc. Revenue in Ovarian Cancer Therapeutics Business (2015-2020)
13.5.5 Genentech Inc. Recent Development
13.6 Astra Zeneca
13.6.1 Astra Zeneca Company Details
13.6.2 Astra Zeneca Business Overview
13.6.3 Astra Zeneca Ovarian Cancer Therapeutics Introduction
13.6.4 Astra Zeneca Revenue in Ovarian Cancer Therapeutics Business (2015-2020)
13.6.5 Astra Zeneca Recent Development
13.7 Boehringer Ingelheim GmbH
13.7.1 Boehringer Ingelheim GmbH Company Details
13.7.2 Boehringer Ingelheim GmbH Business Overview
13.7.3 Boehringer Ingelheim GmbH Ovarian Cancer Therapeutics Introduction
13.7.4 Boehringer Ingelheim GmbH Revenue in Ovarian Cancer Therapeutics Business (2015-2020)
13.7.5 Boehringer Ingelheim GmbH Recent Development
13.8 Hoffmann La Roche Ltd.
13.8.1 Hoffmann La Roche Ltd. Company Details
13.8.2 Hoffmann La Roche Ltd. Business Overview
13.8.3 Hoffmann La Roche Ltd. Ovarian Cancer Therapeutics Introduction
13.8.4 Hoffmann La Roche Ltd. Revenue in Ovarian Cancer Therapeutics Business (2015-2020)
13.8.5 Hoffmann La Roche Ltd. Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Ovarian Cancer Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Ovarian Cancer Therapeutics Revenue
Table 3. Ranking of Global Top Ovarian Cancer Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Ovarian Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of PARP
Table 6. Key Players of PD-L1
Table 7. Key Players of Angiogenesis Inhibitors
Table 8. Global Ovarian Cancer Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Ovarian Cancer Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Ovarian Cancer Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Ovarian Cancer Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Ovarian Cancer Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Ovarian Cancer Therapeutics Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Ovarian Cancer Therapeutics Market Growth Strategy
Table 18. Main Points Interviewed from Key Ovarian Cancer Therapeutics Players
Table 19. Global Ovarian Cancer Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 20. Global Ovarian Cancer Therapeutics Market Share by Players (2015-2020)
Table 21. Global Top Ovarian Cancer Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ovarian Cancer Therapeutics as of 2019)
Table 22. Global Ovarian Cancer Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Ovarian Cancer Therapeutics Product Solution and Service
Table 25. Date of Enter into Ovarian Cancer Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Ovarian Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 28. Global Ovarian Cancer Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Ovarian Cancer Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Ovarian Cancer Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Ovarian Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 32. Global Ovarian Cancer Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Key Players Ovarian Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Ovarian Cancer Therapeutics Market Share (2019-2020)
Table 35. North America Ovarian Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 36. North America Ovarian Cancer Therapeutics Market Share by Type (2015-2020)
Table 37. North America Ovarian Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 38. North America Ovarian Cancer Therapeutics Market Share by Application (2015-2020)
Table 39. Europe Key Players Ovarian Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Ovarian Cancer Therapeutics Market Share (2019-2020)
Table 41. Europe Ovarian Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Ovarian Cancer Therapeutics Market Share by Type (2015-2020)
Table 43. Europe Ovarian Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Ovarian Cancer Therapeutics Market Share by Application (2015-2020)
Table 45. China Key Players Ovarian Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 46. China Key Players Ovarian Cancer Therapeutics Market Share (2019-2020)
Table 47. China Ovarian Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 48. China Ovarian Cancer Therapeutics Market Share by Type (2015-2020)
Table 49. China Ovarian Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 50. China Ovarian Cancer Therapeutics Market Share by Application (2015-2020)
Table 51. Japan Key Players Ovarian Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Ovarian Cancer Therapeutics Market Share (2019-2020)
Table 53. Japan Ovarian Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Ovarian Cancer Therapeutics Market Share by Type (2015-2020)
Table 55. Japan Ovarian Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Ovarian Cancer Therapeutics Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Ovarian Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Ovarian Cancer Therapeutics Market Share (2019-2020)
Table 59. Southeast Asia Ovarian Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Ovarian Cancer Therapeutics Market Share by Type (2015-2020)
Table 61. Southeast Asia Ovarian Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Ovarian Cancer Therapeutics Market Share by Application (2015-2020)
Table 63. India Key Players Ovarian Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 64. India Key Players Ovarian Cancer Therapeutics Market Share (2019-2020)
Table 65. India Ovarian Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 66. India Ovarian Cancer Therapeutics Market Share by Type (2015-2020)
Table 67. India Ovarian Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 68. India Ovarian Cancer Therapeutics Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Ovarian Cancer Therapeutics Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Ovarian Cancer Therapeutics Market Share (2019-2020)
Table 71. Central & South America Ovarian Cancer Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Ovarian Cancer Therapeutics Market Share by Type (2015-2020)
Table 73. Central & South America Ovarian Cancer Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Ovarian Cancer Therapeutics Market Share by Application (2015-2020)
Table 75. Bristol Myers Squibb Company Company Details
Table 76. Bristol Myers Squibb Company Business Overview
Table 77. Bristol Myers Squibb Company Product
Table 78. Bristol Myers Squibb Company Revenue in Ovarian Cancer Therapeutics Business (2015-2020) (Million US$)
Table 79. Bristol Myers Squibb Company Recent Development
Table 80. Eli Lilly and Company Company Details
Table 81. Eli Lilly and Company Business Overview
Table 82. Eli Lilly and Company Product
Table 83. Eli Lilly and Company Revenue in Ovarian Cancer Therapeutics Business (2015-2020) (Million US$)
Table 84. Eli Lilly and Company Recent Development
Table 85. GlaxoSmithKline Plc Company Details
Table 86. GlaxoSmithKline Plc Business Overview
Table 87. GlaxoSmithKline Plc Product
Table 88. GlaxoSmithKline Plc Revenue in Ovarian Cancer Therapeutics Business (2015-2020) (Million US$)
Table 89. GlaxoSmithKline Plc Recent Development
Table 90. Janssen Pharmaceuticals Company Details
Table 91. Janssen Pharmaceuticals Business Overview
Table 92. Janssen Pharmaceuticals Product
Table 93. Janssen Pharmaceuticals Revenue in Ovarian Cancer Therapeutics Business (2015-2020) (Million US$)
Table 94. Janssen Pharmaceuticals Recent Development
Table 95. Genentech Inc. Company Details
Table 96. Genentech Inc. Business Overview
Table 97. Genentech Inc. Product
Table 98. Genentech Inc. Revenue in Ovarian Cancer Therapeutics Business (2015-2020) (Million US$)
Table 99. Genentech Inc. Recent Development
Table 100. Astra Zeneca Company Details
Table 101. Astra Zeneca Business Overview
Table 102. Astra Zeneca Product
Table 103. Astra Zeneca Revenue in Ovarian Cancer Therapeutics Business (2015-2020) (Million US$)
Table 104. Astra Zeneca Recent Development
Table 105. Boehringer Ingelheim GmbH Company Details
Table 106. Boehringer Ingelheim GmbH Business Overview
Table 107. Boehringer Ingelheim GmbH Product
Table 108. Boehringer Ingelheim GmbH Revenue in Ovarian Cancer Therapeutics Business (2015-2020) (Million US$)
Table 109. Boehringer Ingelheim GmbH Recent Development
Table 110. Hoffmann La Roche Ltd. Business Overview
Table 111. Hoffmann La Roche Ltd. Product
Table 112. Hoffmann La Roche Ltd. Company Details
Table 113. Hoffmann La Roche Ltd. Revenue in Ovarian Cancer Therapeutics Business (2015-2020) (Million US$)
Table 114. Hoffmann La Roche Ltd. Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ovarian Cancer Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. PARP Features
Figure 3. PD-L1 Features
Figure 4. Angiogenesis Inhibitors Features
Figure 5. Global Ovarian Cancer Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Hosptial Case Studies
Figure 7. Research Case Studies
Figure 8. Ovarian Cancer Therapeutics Report Years Considered
Figure 9. Global Ovarian Cancer Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Ovarian Cancer Therapeutics Market Share by Regions: 2020 VS 2026
Figure 11. Global Ovarian Cancer Therapeutics Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Ovarian Cancer Therapeutics Market Share by Players in 2019
Figure 14. Global Top Ovarian Cancer Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ovarian Cancer Therapeutics as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Ovarian Cancer Therapeutics Revenue in 2019
Figure 16. North America Ovarian Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Ovarian Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Ovarian Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Ovarian Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Ovarian Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Ovarian Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Ovarian Cancer Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
卵巣がん遺伝子治療の世界市場（～2026年） Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor…- 卵巣がんの世界市場（～2026年） Ovarian cancer is a type of cancer that begins in the ovaries. Ovarian cancer is the most common type of cancer among women. Epithelial tumor, stromal tumor and germ cell tumors are the type of ovarian cancer. North America dominates the global market for ovarian cancer due to large number of aging …
- 転移性卵巣がん治療薬の世界市場（～2026年） Market Analysis and Insights: Global Metastatic Ovarian Cancer Drug Market The global Metastatic Ovarian Cancer Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Metastatic Ovarian Cancer Drug Scope and Market Size …
- 頭頸部がん治療薬の世界市場（～2026年） Head and neck cancer is a group of cancers that starts in the mouth, nose, throat, larynx, sinuses, or salivary glands. Current trends indicate that rising geriatric population worldwide, growing cases of target diseases, and availability of improved healthcare services due to government and private…
- 癌血管新生阻害剤の世界市場（～2026年） Market Analysis and Insights: Global Cancer Angiogenesis Inhibitors Market The global Cancer Angiogenesis Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Cancer Angiogenesis Inhibitors Scope and Market Size …